Oral Therapy

• A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment  

Injection Therapy

• A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis. 

Topical Therapy

• A Phase 1b, Randomized, Vehicle-Controlled, Double-Blind, Pharmacokinetics, Pharmacodynamics, and Safety Study of ARQ-255 Topical Suspension in Healthy Volunteers and Subjects with Alopecia Areata 

Oral Therapy

• A study of Baricitinib (LY3009104) in Children From 6 years to Less Than 18 Years of Age with Alopecia Areata (BRAVE-AA-PEDS)

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (STOP-HS2)

Hidradenitis Suppurativa: Lutikizumab in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa 

Oral Therapy

• A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 (Tranquillo 2) 

Injection Therapy

• A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)